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Background. Human immunodeficiency virus (HIV) replication and immune activation may increase inflam-
mation and coagulation biomarkers. Limited data exist comparing such biomarkers in persons with and without
HIV infection.
Methods. For persons 45–76 years of age, levels of high-sensitivity C-reactive protein (hsCRP), interleukin
(IL)–6, D-dimer, and cystatin C were compared in 494 HIV-infected individuals in the Strategies for Management
of Anti-Retroviral Therapy (SMART) study and 5386 participants in the Multi-Ethnic Study of Atherosclerosis
(MESA) study. For persons 33–44 years of age, hsCRP and IL-6 levels were compared in 287 participants in the
SMART study and 3231 participants in the Coronary Artery Development in Young Adults (CARDIA) study.
Results. hsCRP and IL-6 levels were 55% ( ) and 62% ( ) higher among HIV-infected participantsP ! .001 P ! .001
than among CARDIA study participants. Compared with levels noted in MESA study participants, hsCRP, IL-6,
D-dimer, and cystatin C levels were 50%, 152%, 94%, and 27% higher, respectively ( , for each), amongP ! .001
HIV-infected participants. HIV-infected participants receiving antiretroviral therapy who had HIV RNA lev-
els 400 copies/mL had levels higher (by 21% to 60%) ( ) than those in the general population, for allP ! .001
biomarkers.
Conclusions. hsCRP, IL-6, D-dimer, and cystatin C levels are elevated in persons with HIV infection and re-
main so even after HIV RNA levels are suppressed with antiretroviral therapy. Additional research is needed on
the pathophysiology of HIV-induced activation of inflammatory and coagulation pathways, to guide potential
interventions.
There is a growing body of data indicating that the risk
of serious non-AIDS conditions, such as cardiovascular
disease, kidney disease, liver disease, and non–AIDS-
defining malignancies, is increased in individuals with
human immunodeficiency virus (HIV) infection, com-
pared with the general population [1]. The reasons for
Received 1 September 2009; accepted 14 December 2009; electronically pub-
lished 6 May 2010.
Reprints or correspondence: Ms Jacqueline Neuhaus, Div of Biostatistics, School
of Public Health, University of Minnesota, 2221 University Ave SE, Ste 200, Minne-
apolis, MN 55414 (jacquie@ccbr.umn.edu).
The Journal of Infectious Diseases 2010; 201(12):1788–1795
 2010 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2010/20112-0003$15.00
DOI: 10.1086/652749
this increase are not clear. HIV-induced activation of
inflammatory and coagulation pathways could explain
the increased risk.
In the Strategies for Management of Anti-Retroviral
Therapy (SMART) trial, episodic use of antiretroviral
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treatment (ART) guided by the CD4+ cell count was compared
with the current practice of continuous ART. The episodic ART
strategy was also associated with an 84% ( ) increasedPp .007
risk of all-cause mortality. Most of the deaths were attributed
to serious non-AIDS diseases [2]. A study using stored plasma
specimens for SMART study participants was undertaken to
explore the reasons for the greater risk of death from non-AIDS
diseases in the episodic ART group. Interleukin (IL)–6 and D-
dimer levels were found to increase significantly in the first
month after the interruption of ART. Furthermore, levels of
high-sensitivity C-reactive protein (hsCRP), IL-6, and D-dimer
measured at study entry were strongly associated with mortality,
and the association with mortality was evident in participants
who were assigned to both the episodic and continuous ART
groups [3]. Taken together, the findings from these 3 reports
support the hypothesis that HIV induces activation of inflam-
matory and coagulation pathways, and they suggest that ART
might dampen the effects.
To further understand these findings, we compared the levels
of hsCRP, IL-6, D-dimer, and cystatin C in SMART study par-
ticipants with levels for participants of similar age in 2 large
population-based studies: the Multi-Ethnic Study of Athero-
sclerosis (MESA) study [4] and The Coronary Artery Risk De-
velopment in Young Adults (CARDIA) study [5]. Our hy-
pothesis was that SMART study participants, all of whom were
HIV infected, would have higher values of each of these markers
than either the CARDIA or MESA study participants, who were
recruited from the general population and were unlikely to be
HIV infected.
METHODS
The design, methods, and results of the SMART trial and the
MESA and CARDIA studies have been published elsewhere
[2, 4–6].
SMART study sample. In the SMART study, 5472 men and
women 113 years of age who had CD4+ cell counts 1350 cells/
mm3 were enrolled at 318 sites in 33 countries between January
2002 and January 2006 [2]. Fifty percent of participants were
33–76 years of age and were enrolled at sites in the United
States. hsCRP, IL-6, D-dimer, and cystatin C levels were mea-
sured at baseline in a subset of the randomized participants [3,
7]. SMART participants with prior cardiovascular disease and
participants enrolled at sites outside of the United States were
excluded from the analyses. A total of 287 black and non-
Hispanic, white SMART study participants 33–44 years of age
had hsCRP, IL-6, or D-dimer measurements, and 172 of these
participants also had cystatin C measurements. A total of 494
non-Hispanic white, black, or Hispanic SMART study partic-
ipants 45–76 years of age had levels of hsCRP, IL-6, or D-dimer,
and 231 of these participants also had cystatin C measurements.
The SMART study, including consent for stored specimens,
was approved by the institutional review board at each site and
at the University of Minnesota, which served as the statistical
and data management center. The institutional review board
at the University of Minnesota also approved plans for analysis
of stored specimens for consenting participants.
MESA study sample. In the MESA study, 6814 men and
women 45–84 years of age who were from 4 American racial/
ethnic groups (non-Hispanic white, black, Hispanic, and Chi-
nese) and were without clinical cardiovascular disease were
enrolled from the general population in 6 US communities
between July 2000 and August 2002 [4]. hsCRP, IL-6, D-
dimer, and cystatin C levels were measured from samples
collected at the time of enrollment, and findings for 5386
participants of non-Hispanic white, black, or Hispanic race/
ethnicity who were 45–76 years of age are used in analyses
in this report. HIV infection was not assessed, but there have
been few deaths attributed to HIV/AIDS, and HIV infection
was assumed to be rare.
CARDIA study sample. In the CARDIA study, 5115 black
and non-Hispanic white men and women were enrolled in 4
US communities between March 1985 and June 1986 (year 0)
[5]. After enrollment, 6 additional examinations were con-
ducted. hsCRP and IL-6 were measured at year 15 (in years
2000 and 2001); all covariate values were also taken from the
examination done at year 15. Findings from 3231 participants
33–44 years of age are included in this analysis. Only 2 of the
4 sites measured IL-6 levels. Data comparing the cystatin C
levels in CARDIA study participants and HIV-infected partic-
ipants have already been reported, and CARDIA data in that
report are used to make comparisons with SMART study par-
ticipants (raw data were not available) [8]. As in MESA, HIV
infection status was not assessed and was assumed to be rare.
Biomarker methods. In the SMART and MESA studies, for
consenting participants, specimens stored at baseline were used
to measure the biomarkers. In the CARDIA study, samples
obtained during follow-up were used. Ethylenediaminetetra-
acetic acid plasma specimens were collected and were shipped
frozen to a central repository, where they were stored at70C.
The biomarkers for the SMART, MESA, and CARDIA studies
were measured by the Laboratory for Clinical Biochemistry
Research at the University of Vermont. hsCRP was measured
using the BNII nephelometer (N High Sensitivity CRP; Siemens
Healthcare Diagnostics). The lower limit of detection was 0.16
mg/mL. IL-6 was measured by ultrasensitive enzyme-linked im-
munosorbent assay (ELISA) (Quantikine HS Human IL-6 Im-
munoassay; R&D Systems). The lower limit of detection was
0.16 pg/mL. For D-dimer, an immunoturbidimetric assay (Lia-
test D-DI; Diagnostica Stago) was used on a Sta-R analyzer
(Diagnostica Stago). The lower limit of detection of the assay
was 0.01 mg/mL. A BNII nephelometer (Siemens Healthcare
Diagnostics) that utilized a particle-enhanced immunonephe-
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lometric assay (N Latex Cystatin-C) was used to assay cystatin
C. The assay range is 0.195–7.330 mg/dL. The biological and
laboratory variability of these assays has been described. Intra-
assay coefficients of variation for IL-6, hsCRP, and D-dimer
are 6.3%, 8.9%, and 12.2%, respectively. For cystatin C, the
coefficients of variation range from 2.0% to 2.8% [9–13]. Based
on 3–4 controls per assay, interassay coefficients of variation
range from 7% to 15% for IL-6, 3% to 6% for hsCRP, 5% to
14% for D-dimer, and 2% to 6% for cystatin C (Elaine Cornell,
personal communication).
Statistical methods. This study uses baseline measurements
of hsCRP, IL-6, D-dimer, and cystatin C in 2 age groups from
the SMART study. hsCRP and IL-6 levels in SMART study par-
ticipants 33–44 years of age were compared with the levels for
participants in the same age range in the CARDIA study. Levels
of hsCRP, IL-6, D-dimer, and cystatin C for those 45–76 years
of age in the SMART study were compared with those for MESA
study participants in the same age range. Comparisons were made
for all SMART study participants, for those not receiving ART,
and for those receiving ART who had an HIV RNA level 400
copies/mL. Median values and interquartile ranges for biomarker
levels are cited. Biomarker differences between HIV-infected par-
ticipants in the SMART study and participants in the MESA and
CARDIA studies were compared using analysis of variance after
loge transformation. Other characteristics between participants
in the different studies are compared using Student’s t test and
Fisher’s exact test.
Log-transformed biomarker levels were compared using 3
models with (1) no covariates; (2) covariates corresponding to
age, race, and sex; and (3) covariates corresponding to age,
race, sex, body mass index, smoking status, ratio of total/high-
density lipoprotein (HDL) cholesterol, diabetes history, use of
lipid-lowering drugs, and use of blood pressure–lowering drugs.
The percentage differences between biomarkers levels in par-
ticipants in the SMART and CARDIA studies and between
participants in the SMART and MESA studies were obtained
using the loge-transformed biomarker level by exponentiating
the difference in the mean values. The adjusted percentage
differences derived from the 3 models described above are dis-
played graphically.
To assess the effects of HIV infection and the use of HIV
treatment at study entry on the biomarkers, SMART study
participants were further divided according to their HIV RNA
level and/or whether they were using ART. Within the SMART
study, Pearson correlation coefficients between log10 HIV RNA
and loge biomarker levels were calculated for participants with
an HIV RNA level 1400 copies/mL, according to the ART status
at baseline. In a multiple regression model for each biomarker,
we assessed whether levels varied by class of ART (nonnucleo-
side reverse-transcriptase inhibitors [NNRTIs] with or without
a protease inhibitor [PI], PI [no NNRTI], or nucleoside-reverse
transcriptase inhibitors [NRTIs; no PI or NNRTI]) and by type
of NRTI used (abacavir, no didanosine [ddI], ddI, other NRTI,
and no abacavir or ddI). These analyses were explored because
we previously reported that participants receiving abacavir had
higher inflammatory marker levels than those using NRTIs
other than abacavir or ddI [14]. Comparisons by class of drug
and type of NRTI are not protected by randomization. In ad-
dition to the ART indicators, the aforementioned baseline co-
variates for comparisons with the MESA and CARDIA studies
were included in the regression models.
Coinfection with hepatitis C virus was common in the
SMART study [15]. Thus, separate analyses for SMART study
participants who were not coinfected with hepatitis C virus
were also performed. An earlier study that compared hsCRP
levels for HIV-infected participants with those for CARDIA
participants found that HIV infection without hepatitis C vi-
rus coinfection was associated with higher hsCRP levels in
men but not in women [16]. Thus, we explored possible inter-
actions with sex.
Statistical analyses were performed using SAS software (ver-
sion 9.1; SAS Institute). P values are 2-sided, and 95% confi-
dence intervals (CIs) are cited.
RESULTS
HIV-infected participants in the SMART study were more likely
to be male and black than were participants of similar age in
the CARDIA and MESA studies. HIV-infected participants were
also more likely to smoke cigarettes and take lipid and blood
pressure–lowering drugs; they had higher total cholesterol/HDL
ratios and a lower body mass index than participants in the
CARDIA and MESA studies (Table 1).
Fifty-one percent of SMART participants 33–44 years of age
and 62% of those 45–76 years of age had HIV RNA levels400
copies/mL (Table 1). The majority of participants in the
SMART study were receiving ART. Of these participants re-
ceiving ART, 68% of those 33–44 years of age and 72% of those
45–76 years of age had HIV RNA levels 400 copies/mL. Of
those not receiving ART in the younger group, 29% were ART
naive, and 32% had not used ART for 6 months. Corresponding
percentages for those 45–76 years of age were 20% and 28%,
respectively. CD4+ cell counts averaged 1600 cells/mm3 at study
entry.
Unadjusted levels of hsCRP and IL-6 were 42% ( )Pp .002
and 59% ( ) higher in HIV-infected participants thanP ! .001
in participants in the CARDIA study (Figure 1A). hsCRP, IL-
6, D-dimer, and cystatin C levels were 18% ( ), 118%Pp .003
( ), 52% ( ), and 25% ( ) higher for HIV-P ! .001 P ! .001 P ! .001
infected participants in the SMART study than for participants
in the MESA study (Figure 1B). With adjustment, the percen-
tage differences increased, and all were significant ( ) (Ta-P ! .001
ble 2 and Figure 1A and 1B).
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Table 1. Characteristics of SMART, CARDIA, and MESA Study Participants
Characteristic
Participants 33–44 years of age Participants 45–76 years of age
SMART study
(n p 287)
CARDIA study
(n p 3231) P a
SMART study
(n p 494)
MESA study
(n p 5386) P a
Age, years 40.0  3.1 39.5  3.3 .04 53.0  6.6 60.3  8.9 !.001
Female sex, % of participants 27.5 55.5 !.001 26.5 53.0 !.001
Race/ethnicity, % of participants !.001 !.001
Black 55.4 47.6 49.2 31.9
Latino … … 12.3 24.9
White 44.6 52.4 38.5 43.3
BMI, kg/m2 27.4  5.7 28.7  6.9 .002 27.4  5.7 29.1  5.5 !.001
Ratio of total cholesterol:HDL cholesterol 4.7  2.0 3.9  1.4 !.001 5.1  2.7 4.1  1.3 .004
Total cholesterol level, mg/dL 190.7  41.7 184.2  35.7 .004 197.4  47.4 194.7  36.4 .12
LDL cholesterol level, mg/dL 111.7  32.5 112.6  32.4 .62 111.1  34.7 117.8  31.9 !.001
HDL cholesterol level, mg/dL 45.0  15.9 50.7  14.5 !.001 43.9  15.7 51.0  15.1 !.001
Triglyceride level, mg/dL 179.6  138.4 104.1  86.6 !.001 244.8  229.3 131.1  91.1 !.001
Smoker, % of participants 42.5 22.2 !.001 36.4 15.0 !.001
Diabetes, % of participants 5.6 4.2 .26 13.6 9.7 .46
Receiving BP-lowering drugs, 13.6 7.1 !.001 38.9 32.6 .006
Receiving lipid-lowering drugs, % of
participants
11.1 2.1 !.001 24.9 16.0 !.001
Hepatitis C, % of participants 14.3 24.3
CD4+ cell count, cells/mm3 623  235 657  260
HIV RNA level 400 copies/mL, % of
participants
51.4 62.5
Receiving ART, % of participants 72.5 82.4
NOTE. Data are the mean value  standard deviation, unless otherwise indicated. ART, antiretroviral therapy; BMI, body mass index; BP, blood pressure;
CARDIA, Coronary Artery Development in Young Adults; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; LDL, low-density lipoprotein;
MESA, Multi-Ethnic Study of Atherosclerosis; SMART, Strategies for Management of Anti-Retroviral Therapy.
a For the difference.
Differences according to the use of ART and the HIV RNA
level. With the exception of D-dimer, the biomarkers did not
vary for HIV-infected participants, according to use of ART.
Among HIV-infected participants 33–44 years of age, D-dimer
was 62% (95% CI, 27%–110%) ( ) higher for partici-P ! .001
pants not receiving ART, compared with those receiving ART.
For those 45–76 years of age, D-dimer levels were 63% (95%
CI, 31%–101%) ( ) higher for those not receiving ARTP ! .001
than for those receiving ART. For both groups, study partici-
pants not receiving ART and those receiving ART, D-dimer
levels were significantly higher, compared with levels noted in
MESA study participants; these levels were 127% higher for
those not receiving ART and 39% higher for those receiving
ART ( , for both).P ! .001
Table 3 presents median biomarker levels for study partici-
pants receiving ART who had an HIV RNA level 400 copies/
mL. These levels were also higher than those in the 2 general
population cohorts (Table 2). For HIV-infected participants 33–
44 years of age, the adjusted percentage differences in hsCRP
and IL-6 levels were 40% and 39% higher than those in the
general population ( , for both comparisons). For thoseP ! .001
45–76 years of age, hsCRP, IL-6, D-dimer, and cystatin C levels
were 38%, 60%, 49%, and 21% higher, respectively, than in
the general population ( , for all comparisons).P ! .001
SMART study participants were further subdivided ac-
cording to use of ART and the HIV RNA level (see Table A1
in the appendix, which appears only in the electronic version
of the Journal). P values corresponding to adjusted differences
between those receiving ART who had an HIV RNA level
400 copies/mL and those receiving ART who had an HIV
RNA level 1400 copies/mL for loge-transformed levels of
hsCRP, IL-6, D-dimer, and cystatin-C are , ,Pp .27 Pp .63
, and , respectively.Pp .93 Pp .27
We also explored the correlation of log10 HIV RNA levels
and loge biomarker levels for those receiving ART who had an
HIV RNA level 1400 copies/mL. A significant positive corre-
lation was found between the HIV RNA level and the D-dimer
level, but not the other markers. The correlation coefficients
(P values) were 0.03 ( ), 0.10 ( ), 0.25 (Pp .68 Pp .18 P !
), and 0.01 ( ), for hsCRP, IL-6, D-dimer, and.001 Pp .96
cystatin C, respectively.
Differences according to type and duration of ART. Some
differences were noted in biomarker levels according to type
of ART received in SMART participants. In all cases, however,
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Figure 1. A, Percentage difference in the levels of high-sensitivity C-reactive protein (hsCRP) and interleukin (IL)–6 in human immunodeficiency virus
(HIV)–infected study participants 33–44 years of age vs. the general population. B, Percentage difference in the levels of hsCRP, IL-6, D-dimer, and
cystatin C in HIV-infected study participants 45–76 years of age vs. the general population.
median levels were higher for SMART participants than for
participants in the MESA and CARDIA studies. The median
levels of hsCRP were greater for those receiving an NNRTI
(2.81 mg/mL) versus those receiving a PI (2.14 mg/mL). In a
regression model that adjusted for baseline covariates, hsCRP
levels were 48% higher for those receiving an NNRTI (with
or without a PI) versus a PI alone ( ). Levels of IL-6P ! .001
( ), D-dimer ( ), and cystatin C ( ) didPp .46 Pp .12 Pp .13
not differ significantly between these classes of drugs. Median
levels of hsCRP and IL-6 were higher for those receiving abac-
avir (3.07 mg/mL and 2.70 pg/mL, respectively) versus those
receiving other NRTIs other than ddI (2.39 mg/mL and 2.36
pg/mL, respectively). After adjustment, the hsCRP level was
28% higher for those receiving abacavir, compared with those
receiving other NRTIs other than ddI ( ), and the IL-6Pp .05
level was 19% higher ( ). Also, although median levelsPp .03
of D-dimer were similar for those taking abacavir and other
NRTIs other than ddI (0.27 mg/mL and 0.27 mg/mL, respec-
tively), the adjusted percentage difference was 21% ( ).Pp .054
Cystatin C levels were similar for those receiving abacavir and
other NRTIs (1% difference, ).Pp .81
We also examined whether biomarker levels varied according
to the total number of years of ART use, the number of years
of PI use, and the number of years of NNRTI use, and these
associations were not significant (data not shown).
Differences for smokers and nonsmokers. Because of the
large differences in smoking status between HIV-infected par-
ticipants and participants in the CARDIA and MESA studies,
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Table 2. Median Levels and Interquartile Ranges (IQRs) of Biomarkers for SMART, CARDIA, and MESA Study Participants
Biomarker
Participants 33–44 years of age Participants 45–76 years of age
SMART
(n p 287)a
CARDIA
(n p 3231)b % Diff.c (P)
SMART
(n p 494)d
MESA
(n p 5386) % Diff.c (P)
hsCRP, mg/mL 2.12 (0.80–4.77) 1.36 (0.53–3.78) 55.2 (!.001) 2.68 (1.07–6.01) 2.17 (0.94–4.70) 49.6 (!.001)
IL-6, pg/mL 2.09 (1.26–3.49) 1.29 (0.80–2.07) 62.1 (!.001) 2.63 (1.63–4.18) 1.23 (0.79–1.92) 151.6 (!.001)
D-dimer, mg/mL 0.29 (0.17–0.55) NA (NA) NA 0.34 (0.20–0.61) 0.20 (0.13–0.35) 94.3 (!.001)
Cystatin C, mg/dL 0.94 (0.82–1.07) NA (NA) NA 1.00 (0.88–1.17) 0.85 (0.76–0.96) 27.2 (!.001)
NOTE. CARDIA, Coronary Artery Development in Young Adults; Diff., difference; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; MESA,
Multi-Ethnic Study of Atherosclerosis; NA, not available; SMART, Strategies for Management of Anti-Retroviral Therapy.
a A total of 172 participants had cystatin C levels measured.
b A total of 689 participants had IL-6 levels measured.
c The percentage difference in the means of the log-transformed value, adjusted for age, race, sex, body mass index, smoking, ratio of total cholesterol:
high-density lipoprotein cholesterol, diabetes, lipid-lowering therapy, and blood pressure–lowering therapy.
d A total of 231 participants had cystatin C levels measured.
Table 3. Biomarkers Levels in SMART Study Participants Receiving Antiretroviral Therapy (ART) Who
Had an HIV RNA Level 400 Copies/mL and Percentage Differences in Levels Versus CARDIA and MESA
Study Participants, as Cited in Table 2
Biomarker
Participants 33–44 years of age Participants 45–76 years of age
No.
Median
level (IQR) % Diff. (P) No.
Median
level (IQR) % Diff. (P)
hsCRP, mg/mL 140 2.13 (0.77–5.20) 40.2 (!.001) 293 2.83 (1.07–6.80) 37.8 (!.001)
IL-6, pg/mL 139 1.89 (1.15–3.42) 39.0 (!.001) 291 2.64 (1.55–4.14) 60.1 (!.001)
D-dimer, mg/mL 140 0.21 (0.15–0.46) NA 293 0.29 (0.17–0.57) 49.1 (!.001)
Cystatin C, mg/dL 86 0.90 (0.78–0.97) NA 130 1.00 (0.86–1.16) 20.9 (!.001)
NOTE. Data are the median level and (interquartile range [IQR]). CARDIA, Coronary Artery Development in Young Adults;
Diff., difference; MESA, Multi-Ethnic Study of Atherosclerosis; NA, not available; SMART, Strategies for Management of Anti-
Retroviral Therapy.
separate analyses were conducted for nonsmokers. Adjusted
hsCRP and IL-6 levels were 50% (95% CI, 26%–79%) and
63% (95% CI, 46%–83%) higher in nonsmoking HIV-infected
participants than in nonsmoking participants in the CARDIA
study. For nonsmokers in the SMART study, compared with
nonsmokers in the MESA study, levels of hsCRP, IL-6, D-dimer,
and cystatin C were 60% (95% CI, 41%–81%), 164% (95%
CI, 146%–184%), 88% (95% CI, 70%–108%), and 29% (95%
CI, 25%–34%) higher, respectively.
Differences according to sex and hepatitis C virus infection.
In all 3 studies, hsCRP levels were higher in women than men.
In the SMART study, median (IQR) levels were 3.81 mg/mL
(1.23–7.50 mg/mL) for women and 2.08 mg/mL (0.92–4.66 mg/
mL) for men. There was evidence of an interaction between
sex and HIV for hsCRP ( , for comparison with theP ! .001
CARDIA study; , for comparison with the MESA study)Pp .01
but not for the other biomarkers. Both men and women with
HIV infection had higher adjusted levels of hsCRP than par-
ticipants of the same sex in the CARDIA and MESA studies,
but relative differences were larger for men (77% [ ]P ! .001
higher than in the CARDIA study and 60% [ ] higherP ! .001
than in the MESA study) than for women (9% [ ] higherPp .48
than in the CARDIA study and 26% [ ] higher than inPp .02
the MESA study).
Differences in hsCRP levels between HIV-infected study par-
ticipants and those in the CARDIA and MESA study cohorts
were greater when SMART study participants with hepatitis C
virus coinfection were excluded (22% of men and 18% of
women in the SMART study) (information to make a similar
exclusion was not available for the CARDIA and MESA studies,
but the prevalence of hepatitis C virus infection was assumed
to be low). hsCRP levels were 97% higher ( ) for HIV-P ! .001
infected men in both age groups (the SMART study vs. the
CARDIA study and the SMART study vs. the MESA study).
The corresponding percentage differences for women were 25%
( ) (the SMART study vs. the CARDIA study) and 62%Pp .11
( ) (the SMART study vs. the MESA study). For bothP ! .001
age groups, the interaction with sex persisted ( , forPp .001
comparison with the CARDIA study; , for comparisonPp .05
with the MESA study) after the exclusion of participants in the
SMART study who had hepatitis C virus infection.
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DISCUSSION
We compared the levels of 4 biomarkers between HIV-infected
study participants and participants in 2 large population-based
studies. Each of the biomarkers has been associated with car-
diovascular disease in the general population [17–24], and 3
of the biomarkers (hsCRP, IL-6, and D-dimer) have recently
been associated with all-cause mortality in the SMART study
[3]. Compared with participants in the general population co-
horts, CARDIA and MESA HIV-infected individuals in the
SMART study had higher levels of inflammatory markers, as
measured by hsCRP and IL-6; coagulation and fibrinolysis ac-
tivity, as measured by D-dimer; and impaired renal function,
as measured by cystatin C. Higher levels of these markers were
evident even among HIV-infected study participants who were
receiving ART and had HIV RNA levels 400 copies/mL.
The elevation of these biomarker levels among HIV-infected
persons receiving effective ART as well as among those not re-
ceiving ART may reflect ongoing immune activation even with
successful suppression of HIV replication [25]. Given the mag-
nitude of the elevations and their association with cardiovascular
disease, renal disease, and all-cause mortality in the general pop-
ulation, as well as with all-cause mortality in the SMART study,
treatments that target inflammatory and coagulation pathways
and decrease hsCRP, IL-6, and D-dimer levels may warrant in-
vestigation among patients with HIV infection [26, 27]. Among
SMART study participants, some differences were noted in bio-
marker levels according to NNRTI and PI use and according to
NRTI type. For the latter, we found higher levels of hsCRP and
IL-6 among participants taking abacavir, compared with those
taking other NRTIs other than ddI. This finding is consistent
with a previous report on the SMART study cohort [14]. Dif-
ferences among ART drugs are best explored in randomized
studies, and these findings indicate that these markers should be
considered in future trials of ART regimens.
Only a few studies have compared these biomarkers between
participants with HIV infection and uninfected controls. hsCRP
has been the focus of several reports [16, 28, 29]. In the largest
study, the Fat Redistribution and Metabolic Change in HIV
Infection (FRAM) study, hsCRP levels were elevated in HIV-
infected men but not women, compared with HIV-uninfected
participants in the CARDIA study, and the differences between
HIV-infected and HIV-negative participants varied according
to coinfection with hepatitis C virus [16]. Like the FRAM study,
our study found that HIV infection was associated with greater
differences in hsCRP levels for men, compared with women.
The reasons for this finding are unclear. We also found that
differences in hsCRP levels between those with HIV infection
and those in the general population were smaller for those with
hepatitis C virus coinfection, compared with those without
hepatitis C virus coinfection. Reasons for differences in hsCRP
levels according to hepatitis C status are likely multifactorial,
although hsCRP is primarily synthesized by hepatocytes, and
differences in hepatic function among patients coinfected with
HIV and hepatitis C virus, compared with patients with hep-
atitis C virus monoinfection, may be a contributing factor to
the hsCRP difference between coinfected and monoinfected par-
ticipants [30].
In the FRAM study, cystatin C levels were also compared
with those in participants in the CARDIA study [8]. Levels
were higher in HIV-infected participants, compared with par-
ticipants in the CARDIA study, after adjustment for demo-
graphic and clinical factors. Cystatin C may reflect, in part,
ongoing inflammation as well as loss of kidney function. We
recently showed that cystatin C levels increased rapidly after
ART interruption and that cystatin C levels were correlated
with inflammatory and coagulation markers [7].
The strengths of this investigation include the use of a single
laboratory for the measurement of biomarkers in the SMART,
CARDIA, and MESA studies. The age range and sex-ethnic
distribution of SMART permitted comparisons across a broad
spectrum of people with HIV infection. A weakness is that the
SMART study did not exclude participants with more advanced
HIV infection and included few ART-naive participants. Fur-
thermore, there were many differences between the participants
in the SMART study and those in the CARDIA and MESA
studies. Although many factors were considered in the multi-
variate analyses and they did not have a substantial effect on
the results, and although several subgroup analyses were con-
sidered, it is possible that there are other differences that explain
our findings. Finally, because these were cross-sectional com-
parisons, the temporal relationship between the biomarkers and
some of the predictors considered is uncertain. In summary,
we found that markers of inflammation, coagulation, and renal
function were elevated in HIV-infected study participants re-
ceiving or not receiving ART, compared with participants in 2
large population-based studies. Additional research on the rea-
sons for these elevations and the interventions required to low-
er them is needed.
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